<h4>Introduction to Snake Venom Neutralising Antibody</h4><p>Researchers at the <strong>Indian Institute of Science (IISc)</strong> in <strong>Bengaluru</strong> have developed a groundbreaking <strong>synthetic human antibody</strong>.</p><p>This antibody is designed to neutralise a potent <strong>neurotoxin</strong> produced by <strong>krait snakes</strong> and other <strong>elapids</strong>.</p><div class='info-box'><p><strong>Elapids</strong> are a diverse family of <strong>venomous snakes</strong>. They possess <strong>hollow, front fangs</strong> that efficiently deliver venom.</p><p>This family includes over <strong>300 species</strong> globally, found in various habitats, such as <strong>cobra, king cobra, krait,</strong> and <strong>black mamba</strong>.</p></div><h4>The New Venom-Neutralising Antibody: Development and Methodology</h4><p>The <strong>IISc team</strong> successfully adapted a previously established approach for creating antibodies against <strong>HIV</strong> and <strong>COVID-19</strong>.</p><p>This marks the <strong>first application</strong> of this specific strategy for <strong>snakebite treatment</strong>, highlighting its innovative nature.</p><div class='key-point-box'><p><strong>Methodology:</strong> The synthetic antibody targets a <strong>conserved region</strong> within the core of the <strong>three-finger toxin (3FTx)</strong>.</p><p>This <strong>3FTx</strong> is a common component found in the venoms of various <strong>elapid species</strong>, despite variations in the toxin itself.</p></div><h4>Effectiveness and Potency</h4><p>Researchers rigorously tested their <strong>synthetic antibody</strong> on <strong>animal models</strong>.</p><p>It demonstrated significant effectiveness against toxins from the <strong>Taiwanese banded krait, monocled cobra,</strong> and <strong>black mamba</strong>.</p><div class='info-box'><p>The synthetic antibody showed a potency nearly <strong>15 times greater</strong> than conventional antivenom.</p><p>Crucially, it remained effective even when administered with a <strong>delay</strong> following venom injection, offering a wider therapeutic window.</p></div><h4>Distinction from Conventional Antivenom</h4><p><strong>Conventional antibodies</strong>, used in traditional antivenom, are not uniform in composition.</p><p>They are a mixture of different types of molecules with varying affinity and specificity to different <strong>epitopes</strong> of the antigen.</p><div class='key-point-box'><p>The new synthetic antibody offers a more targeted and potentially more consistent treatment due to its specific design against a conserved region.</p></div><h4>The Urgent Need for Better Snakebite Treatment</h4><p><strong>Snakebites</strong> are a significant public health crisis, causing thousands of deaths annually.</p><p>The burden is particularly severe in regions like <strong>India</strong> and <strong>sub-Saharan Africa</strong>.</p><div class='info-box'><p>According to an <strong>Indian Council of Medical Research (ICMR)</strong> study, India recorded approximately <strong>1.2 million (12 lakh) snakebite fatalities</strong> between <strong>2000 and 2019</strong>.</p><p>This averages out to an alarming <strong>58,000 deaths annually</strong> due to snakebites in India.</p></div><div class='exam-tip-box'><p>Understanding the <strong>burden of snakebites</strong> and advancements in their treatment is crucial for <strong>UPSC Mains GS Paper 3 (Science and Technology)</strong> and <strong>GS Paper 2 (Health)</strong>. Mentioning <strong>ICMR data</strong> adds factual weight to your answers.</p></div>